SOURCE: Mount Tam Biotechnologies

Mount Tam Biotechnologies

December 18, 2015 11:00 ET

Mount Tam Biotechnologies Engages Richard Marshak for Strategic Participation

NOVATO, CA--(Marketwired - Dec 18, 2015) - Mount Tam Biotechnologies ("Mount Tam") (OTC PINK: MNTM), announced today that it has entered into a strategic participation agreement with Dr. Richard Marshak as a consultant and development head. Dr. Marshak brings 18 years of pharmaceutical experience across a wide range of leadership roles. At Abbott/Abbvie, he occupied roles of increasing responsibility spanning product marketing across a broad range of therapeutic areas, business development, general manager Pain Care, and general manager, alliance management and strategic planning. 

Brian Kennedy, Ph.D., Chairman of Mount Tam, and CEO of the Buck Institute for Research on Aging, said, "our goal in retaining Richard is to focus the substantial IP portfolio and research capabilities of the Buck and Mount Tam Biotechnologies towards the development of medicines that can benefit patients through our proprietary technologies around mTOR inhibition, and to help Mount Tam continue to move forward as the leader in this exciting field."

As founder of LF Consulting, Head of Corporate Development at Health Systems Reform, and a former general manager at Abbott/Abbvie, his noteworthy skills include strategic planning, strategic alliances, pharmaceutical sales, clinical development, product launch, and market access.

Dr. Marshak said, "I am excited to begin the process of outlining our major goals for 2016, including optimizing clinical development pathways, further developing our understanding of unmet needs across a broad range of potential indications where Mount Tam technology can be applied, and the review of issued and filed IP while exploring options to further strengthening Mount Tam's IP portfolio. I'm very excited to be working with Mount Tam and look forward to entering 2016 together."

Since leaving Abbvie in 2013, Dr. Marshak has provided consulting services to a wide range of development stage life science companies, with a focus on guiding prioritization of development pathways and optimizing commercialization planning as well as overall strategic planning. Dr. Marshak's qualifications include an MBA from the Chicago School of Business, and a Veterinary Medical Degree and BA from the University of Pennsylvania. 

About Mount Tam Biotechnologies, Inc.

Formed on World Lupus Day 2014, Mount Tam Biotechnologies, Inc. was established to develop, optimize and bring to market leading medical compounds to better the health and well-being of millions of people who have been affected by autoimmune diseases. The organization's most advanced product focuses on the treatment of systemic lupus erythematosus (SLE). 

Mount Tam has partnered with the world-renowned Buck Institute for Research on Aging through a worldwide exclusive licensing and collaboration agreement. The assets, which are focused on autoimmune diseases, are highly target-specific polyketides -- a class of compounds with an extremely successful track record with the F.D.A. drug approval process. The assets are supported by intellectual property consisting of over 45 worldwide issued patents and patent applications, including composition of matter, manufacturing and therapeutic area applications.

Mount Tam is applying its first and most advanced asset, TAM-01, to the Investigational New Drug (IND) application phase of the FDA. It has already completed extensive non-GLP pre-clinical development. The primary focus is to develop TAM-01 for the treatment of systemic lupus erythematosus (SLE) in an expanding orphan drug market. Mount Tam will use the R&D conducted on TAM-01 as the core science for additional assets, including its second product known as TAM-02, which is focused on multiple sclerosis (MS).

For more information visit www.MountTamBiotech.com

This press release may contain "forward-looking" information within the meaning of the Private Securities Litigation Reform Act of 1995. In accordance with the safe harbor provisions of this Act, statements contained herein that look forward in time that include everything other than historical information, involve risks and uncertainties that may affect the Company's actual results. There can be no assurance that such statements will prove to be accurate and there are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, plans and objectives of management for future operations or products, the market acceptance or future success of our products, and our future financial performance. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in its most recent filings with the U S. Securities and Exchange Commission (available at http://www.sec.gov). The Company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Contact Information

  • Investor and Media Contact:

    Mr. David R. Wells
    Chief Financial Officer
    Mount Tam Biotechnologies

    Phone: (415) 488 6041
    E-mail: contact@mounttambiotech.com